
Rajesh Narendran

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4450801/publications.pdf Version: 2024-02-01



RAIESH NADENDRAN

#	Article	IF	CITATIONS
1	Beyond monoamines: I. Novel targets and radiotracers for Positron emission tomography imaging in psychiatric disorders. Journal of Neurochemistry, 2023, 164, 364-400.	3.9	7
2	Prefrontal and Striatal Dopamine Release Are Inversely Correlated in Schizophrenia. Biological Psychiatry, 2022, 92, 791-799.	1.3	17
3	Imaging beta-amyloid (Aβ) burden in the brains of middle-aged individuals with alcohol-use disorders: a [11C]PIB PET study. Translational Psychiatry, 2021, 11, 257.	4.8	3
4	Imaging the influence of red blood cell docosahexaenoic acid status on the expression of the 18KDa translocator protein in the brain: a [11C]PBR28 PET study in young healthy males. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2021, , .	1.5	2
5	NOP receptor antagonism reduces alcohol drinking in male and female rats through mechanisms involving the central amygdala and ventral tegmental area. British Journal of Pharmacology, 2020, 177, 1525-1537.	5.4	25
6	Distinguishing Schizophrenia Subtypes: Can Dopamine Imaging Improve the Signal-to-Noise Ratio?. Biological Psychiatry, 2020, 87, 197-199.	1.3	6
7	Acute Elevations in Cortisol Increase the InÂVivo Binding of [11C]NOP-1A to Nociceptin Receptors: A Novel Imaging Paradigm to Study the Interaction Between Stress- and Antistress-Regulating Neuropeptides. Biological Psychiatry, 2020, 87, 570-576.	1.3	9
8	lmaging Cortical Dopamine Transmission in Cocaine Dependence: A [11C]FLB 457–Amphetamine Positron Emission Tomography Study. Biological Psychiatry, 2020, 88, 788-796.	1.3	5
9	Nociceptin Receptors Upregulated in Cocaine Use Disorder: A Positron Emission Tomography Imaging Study Using [¹¹ C]NOP-1A. American Journal of Psychiatry, 2019, 176, 468-476.	7.2	13
10	Decreased Nociceptin Receptors Are Related to Resilience and Recovery in College Women Who Have Experienced Sexual Violence: Therapeutic Implications for Posttraumatic Stress Disorder. Biological Psychiatry, 2019, 85, 1056-1064.	1.3	19
11	Imaging phosphodiesteraseâ€10a availability in cocaine use disorder with [¹¹ C]IMA107 and PET. Synapse, 2019, 73, e22070.	1.2	7
12	Amphetamine-Induced Striatal Dopamine Release Measured With an Agonist Radiotracer inÂSchizophrenia. Biological Psychiatry, 2018, 83, 707-714.	1.3	24
13	Nociceptin Receptors in Alcohol Use Disorders: AÂPositron Emission Tomography Study Using [11C]NOP-1A. Biological Psychiatry, 2018, 84, 708-714.	1.3	25
14	An openâ€label positron emission tomography study to evaluate serotonin transporter occupancy following escalating dosing regimens of (<i>R</i>)â€(–)â€ <i>O</i> â€desmethylvenlafaxine and racemic <i>O</i> â€desmethylvenlafaxine. Synapse, 2018, 72, e22021.	1.2	6
15	Failure to detect amphetamineâ€induced dopamine release in the cortex with [¹¹ C]FLB 457 positron emission tomography (PET): Methodological considerations. Synapse, 2018, 72, e22037.	1.2	4
16	Brain translocator protein occupancy by ONOâ€2952 in healthy adults: A Phase 1 PET study using [¹¹ C]PBR28. Synapse, 2017, 71, e21970.	1.2	7
17	Imaging corticotropin-releasing-factor and nociceptin in addiction and PTSD models. International Review of Psychiatry, 2017, 29, 567-579.	2.8	8
18	Constance E. Lieber, Theodore R. Stanley, and the Enduring Impact of Philanthropy on Psychiatry Research. Biological Psychiatry, 2016, 80, 84-86.	1.3	2

Rajesh Narendran

#	Article	IF	CITATIONS
19	Cortical Dopamine Transmission as Measured with the [11C]FLB 457 – Amphetamine PET Imaging Paradigm Is Not Influenced by COMT Genotype. PLoS ONE, 2016, 11, e0157867.	2.5	5
20	Decreased Vesicular Monoamine Transporter Type 2 Availability in the Striatum Following Chronic Cocaine Self-Administration in Nonhuman Primates. Biological Psychiatry, 2015, 77, 488-492.	1.3	15
21	Deficits in Prefrontal Cortical and Extrastriatal Dopamine Release in Schizophrenia. JAMA Psychiatry, 2015, 72, 316.	11.0	304
22	In Vivo Measurement of GABA Transmission in Healthy Subjects and Schizophrenia Patients. American Journal of Psychiatry, 2015, 172, 1148-1159.	7.2	92
23	Safety of Oral Amphetamine Administered during Positron Emission Tomography Scans in Medically Screened Humans. PLoS ONE, 2015, 10, e0140647.	2.5	1
24	Imaging of Neurochemical Transmission in the Central Nervous System. , 2014, , 453-484.		0
25	Decreased Prefrontal Cortical Dopamine Transmission in Alcoholism. American Journal of Psychiatry, 2014, 171, 881-888.	7.2	55
26	Amphetamineâ€induced release of dopamine in primate prefrontal cortex and striatum: striking differences in magnitude and timecourse. Journal of Neurochemistry, 2014, 130, 490-497.	3.9	28
27	Cocaine Abuse in Humans Is Not Associated with Increased Microglial Activation: An 18-kDa Translocator Protein Positron Emission Tomography Imaging Study with [11C]PBR28. Journal of Neuroscience, 2014, 34, 9945-9950.	3.6	55
28	Prefrontal Response and Frontostriatal Functional Connectivity to Monetary Reward in Abstinent Alcohol-Dependent Young Adults. PLoS ONE, 2014, 9, e94640.	2.5	69
29	Reproducibility of Post-Amphetamine [11C]FLB 457 Binding to Cortical D2/3 Receptors. PLoS ONE, 2013, 8, e76905.	2.5	17
30	In Vivo Evidence for Low Striatal Vesicular Monoamine Transporter 2 (VMAT2) Availability in Cocaine Abusers. American Journal of Psychiatry, 2012, 169, 55-63.	7.2	44
31	Improved Working Memory but No Effect on Striatal Vesicular Monoamine Transporter Type 2 after Omega-3 Polyunsaturated Fatty Acid Supplementation. PLoS ONE, 2012, 7, e46832.	2.5	28
32	Amphetamine induced dopamine release increases anxiety in individuals recovered from anorexia nervosa. International Journal of Eating Disorders, 2012, 45, 263-271.	4.0	47
33	Positron emission tomography imaging of dopamine D2/3 receptors in the human cortex with [¹¹ C]FLB 457: Reproducibility studies. Synapse, 2011, 65, 35-40.	1.2	41
34	Evaluation of dopamine D _{2/3} specific binding in the cerebellum for the positron emission tomography radiotracer [¹¹ C]FLB 457: Implications for measuring cortical dopamine release. Synapse, 2011, 65, 991-997.	1.2	35
35	Imaging of dopamine <i>D</i> _{2/3} agonist binding in cocaine dependence: A [¹¹ C]NPA positron emission tomography study. Synapse, 2011, 65, 1344-1349.	1.2	28
36	No effect of dopamine depletion on the binding of the high-affinity D2/3 radiotracer [11C]FLB 457 in the human cortex. Synapse, 2010, 64, 879-885.	1.2	14

#	Article	IF	CITATIONS
37	A Comparative Evaluation of the Dopamine D _{2/3} Agonist Radiotracer [¹¹ C](â^)- <i>N</i> -Propyl-norapomorphine and Antagonist [¹¹ C]Raclopride to Measure Amphetamine-Induced Dopamine Release in the Human Striatum. Journal of Pharmacology and Experimental Therapeutics, 2010, 333, 533-539.	2.5	78
38	Imaging Neurotransmitter Release by Drugs of Abuse. Current Topics in Behavioral Neurosciences, 2010, 3, 219-245.	1.7	41
39	Lower Level of Endogenous Dopamine in Patients With Cocaine Dependence: Findings From PET Imaging of D ₂ /D ₃ Receptors Following Acute Dopamine Depletion. American Journal of Psychiatry, 2009, 166, 1170-1177.	7.2	148
40	Human Biodistribution and Dosimetry of the D2/3 Agonist 11C-N-Propylnorapomorphine (11C-NPA) Determined from PET. Journal of Nuclear Medicine, 2009, 50, 814-817.	5.0	17
41	Positron emission tomography imaging of amphetamineâ€induced dopamine release in the human cortex: A comparative evaluation of the high affinity dopamine D _{2/3} radiotracers [¹¹ C]FLB 457 and [¹¹ C]fallypride. Synapse, 2009, 63, 447-461.	1.2	127
42	Positron emission tomography imaging of D _{2/3} agonist binding in healthy human subjects with the radiotracer [¹¹ C]â€ <i>N</i> â€propylâ€norapomorphine: Preliminary evaluation and reproducibility studies. Synapse, 2009, 63, 574-584.	1.2	24
43	Cocaine abuse and sensitization of striatal dopamine transmission: A critical review of the preclinical and clinical imaging literature. Synapse, 2008, 62, 851-869.	1.2	81
44	Amphetamine-Induced Dopamine Release: Markedly Blunted in Cocaine Dependence and Predictive of the Choice to Self-Administer Cocaine. American Journal of Psychiatry, 2007, 164, 622-629.	7.2	345
45	Amphetamine-induced dopamine release: Duration of action as assessed with the D2/3 receptor agonist radiotracer (––)-N-[11C]propyl-norapomorphine ([11C]NPA) in an anesthetized nonhuman primate. Synapse, 2007, 61, 106-109.	1.2	30
46	Dopamine (D2/3) receptor agonist positron emission tomography radiotracer [11C]-(+)-PHNO is a D3 receptor preferring agonist in vivo. Synapse, 2006, 60, 485-495.	1.2	159
47	Estimation of serotonin transporter parameters with 11C-DASB in healthy humans: reproducibility and comparison of methods. Journal of Nuclear Medicine, 2006, 47, 815-26.	5.0	69
48	Measurement of the Proportion of D2 Receptors Configured in State of High Affinity for Agonists in Vivo: A Positron Emission Tomography Study Using [11C]N-Propyl-norapomorphine and [11C]Raclopride in Baboons. Journal of Pharmacology and Experimental Therapeutics, 2005, 315, 80-90.	2.5	57
49	Altered Prefrontal Dopaminergic Function in Chronic Recreational Ketamine Users. American Journal of Psychiatry, 2005, 162, 2352-2359.	7.2	149
50	In vivo vulnerability to competition by endogenous dopamine: Comparison of the D2 receptor agonist radiotracer (-)-N-[11C]propyl-norapomorphine ([11C]NPA) with the D2 receptor antagonist radiotracer [11C]-raclopride. Synapse, 2004, 52, 188-208.	1.2	145
51	Quantitative analysis of (-)-N-(11)C-propyl-norapomorphine in vivo binding in nonhuman primates. Journal of Nuclear Medicine, 2004, 45, 338-46.	5.0	24